Good afternoon, and welcome to the KemPharm Third Quarter 2022 Corporate and Financial Results Conference Call. Currently, all callers have been placed in a listen-only mode and following management’s prepared remarks, the call will be opened up for questions. Please be advised that today’s call is being recorded. I will now turn the call over to Nichol Ochsner, KemPharm’s Vice President, Investor Relations and Corporate Communications. Thank you. Ma’am, you may begin.

Good afternoon and thank you for joining our call to discuss KemPharm’s third quarter 2022 financial and corporate results. Before we begin, I would like to remind our listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties and are subject to changes at any time, including but not limited to, statements about KemPharm’s expectations regarding future operating results. Forward-looking statements are made pursuant to the Safe Harbor provisions of the federal securities laws and represent management’s current expectations. Actual results may differ materially. KemPharm disclaims any obligation to update or revise forward-looking statements except as required by law. For complete information regarding forward-looking statements, risks and uncertainties can be found in KemPharm’s filings with the SEC, which are available on KemPharm’s website under the Investor Relations section. Speaking on today’s call will be Travis Mickle, KemPharm’s President and CEO; and LaDuane Clifton, CFO. Following remarks Travis and LaDuane will participate in a question-and-answer session. With that it is my pleasure to introduce, Travis.

Thank you, Nichol. And thank you everyone for joining us again today. For those that are not familiar with KemPharm. I would like to give just a brief introductory statement. KemPharm is focused on the development and discovery of novel rare CNS and neurodegenerative disorders as well as lysosomal storage diseases. While historically, we have a number of other assets that have been licensed, our new focus is on the development of potential products that we could internally commercialize. That is all built on the foundation of strong science as well as good foundation of financial -. So a strong balance sheet. Next slide, please. Just to go over briefly the recent highlights and from the press release, and results from the Q3. Of course, there is a number of different things going on with arimoclomol and many of these. We have not continuously updated, but just as a highlight, we recently had the completion of the four year open label safety trial for arimoclomol, demonstrating a long term effect as well as safety of arimoclomol over that time period. We have been having ongoing collaborative dialogue with the FDA. This includes meetings, submissions, back and forth with questions and answers and so forth. So a very collaborative discussion there. And we have been working to bring in all the new data as well as some of the other data that we weren’t expecting to have to add to the NDA. Based on all of that, we are now targeting the resubmission as early as Q3 of next year. AZSTARYS continues to generate sales and milestones, potential for the royalty revenue with AZSTARYS. We know that Corium is continuing their effort there. KP1077 development program is going well. We have just announced results of the Phase I cardiovascular trial. Certainly…

Thanks, Travis. As Travis mentioned earlier in his opening remarks, we had another positive quarter, a good quarter and specifically our balance sheet remains very strong. Revenue reported for this quarter is 2.9 million which is net certain liability, associated with a remarkable EAP program that is coming in as we expected. Our net loss for the quarter is about $0.19 per basic and diluted share, which was driven primarily by R&D expense and G&A expense. But again, offset by the net revenues. As of September 30, our cash balance was $107.4 million and that is a decrease of about $7 million compared to the prior quarter. It really was comprised of sort of the ongoing third-party R&D cost as well as other expenses and notably investment of working capital related to a French EAP program. So you will see on our balance sheet that there was an increase in accounts receivable. And so as we move forward, we do expect that cash flow to begin operating in a normal course. Ultimately, our cash balance based on our current operating forecast allows our resources to extend our runway into 2026. And also as Travis has mentioned to the extent that AZSTARYS generates royalty revenue or additional milestones, which we still see as pretty much an important thing to be looking for, that will have the effect of potentially extending that runway further. Thank you and Travis back to you.

Thanks, LaDuane. So just looking forward as we go and review the upcoming milestones kind of reiterates our intention to re-file the NDA, Q3 of next year, anticipate of course, the quarterly revenue from the French EAP program. SARS will continue to monitor scripts and see how that goes. I think that those are certainly tracking in the right direction for KP1077. Have the expectation for the trial to start by the end of the year. Interim results should be available mid-year with those particular final results by the year end, as well as the initiation of a narcolepsy trial sometime in 2023. And then as LaDuane highlighted again, solid balance sheet, a lot of good possible expansion opportunities, not just with our pipeline, but through what we already have in arimoclomol and KP1077 and certainly a long runway that can only be bolstered by additional revenue. So with that, I’m actually going to turn it over and see if there is any questions.

Our first question will come from Sumant Kulkarni with Canaccord. Your line is open.

Definitely. Thanks for taking my questions. I have a bunch here, so I will start with one. It looks like at this time you don’t have any new requests from the FDA, but has the agency already finished reviewing the new data that you’ve generated? If not, when do you think the FDA could finish that? And how confident are you that the FDA’s new analysis will not lead to the need for a new clinical trial?

I mean, it is an ongoing sort of review. So we have submitted, and I won’t give particular details, but whatever we have submitted to the agency, they have fully reviewed. There will be a detailed review post-mission. I mean, that is just standard course, but they have already asked questions and weighed in on some of the information. That is not the totality of that information, where we could actually file the NDA if it were. We have more to provide them as well as more to put into the NDA that they won’t be able to review until then. So I hope that answers your question.

Yes. And then it seems like the safety study is the new piece of information that is the key thing that led you to this potential - like the delay in the potential filing. So were there any specific findings in the safety study that you might consider new or counterintuitive relative to the safety data that is already publicly known on arimoclomol? And is there any risk related to continuation of an EAP program for the product based on the new safety data?

I mean, that particular study and the results, it actually did as well measure the NPCCSS. The efficacy score was continuously measured as well. Actually, showed a long and lasting effect of arimoclomol in those patients who were in the study, which would have been not just four years, but five years in total. And additionally, there were no safety signals that were different than there was in the double blinded phase of the trial. I think the data is great. It is already been presented by Mark Patterson at two NPC conferences, including the conference, and then the conference back in July. So those results are already out there. Certainly, we can put those up on our website at some point here. I think they are helpful. I think there is also results of the two failed trials that Orphazyme attempted with ALS and IBM that show again So again, the safety here 500 plus patients, there has been no significant safety signal from arimoclomol in all of that. And that is pretty rare to have in this type of disease that level of safety and that many patients exposed for a long period of time.

And then one more before I hop back into the queue. Could you give us any details on what specific parts of the proposed NDA package may be most in need of strengthening that led to this push out in the timeline and will you say that the new timeline is conservative relative to the information needed to be generated?

Yes. I would say, it is conservative. I think the difference between March and July is Q1 to Q3. So it doesn’t certainly have to indicate a six or nine-month delay from those sort of things. But When we looked at what needed to be bolstered, there was nothing. I mean, we really had all the data. It is all about putting it together. And then what has kind of led to this is the safety trial. It wasn’t something we anticipated putting into the submission. So that has to go in and we really do believe it is a cornerstone of our arguments for the benefit, as well as a sequential sort of submission pattern. The agency wants to see something and they want more from that. So we can’t do things in parallel as much as we would like to. And so, it is that sequential pattern of providing more getting feedback, going back maybe meeting with them formally or informally that has kind of pushed it out a little bit, which again I think is entirely very positive, because we have never received anything back that has indicated otherwise.

Very helpful. Thank you.

Thank you. Our next question will come from Jonathan Aschoff with Roth Capital Partners. Your line is open.

Thank you, guys. Good evening. Would you break down the revenue to an extent if you can, because it is not one 100% arimoclomol France. Can you help us out with just that?

Yes. There was a portion of that that was royalties that came into from net sales of AZSTARYS as a percentage of that. And you will see when we follow our 10-Q that was around we had around, we recognized about 200,000 or so of royalty revenue on AZSTARYS.

Okay. So it is simply about 2.7 Aramchololol, 200 AZSTARYS and no other line item, right?

Yes.

Thank you very much guys.

Thank you. This does conclude the Q&A portion of today’s call. And I would now like to turn it back to Travis Mickle for any additional or closing remarks. Thank you.

Thank you again for your participation and joining us today. I appreciate the good questions, initial analysis and hopefully additional color on what we are doing and what we hope to achieve, not just our remainder of this year, but next year as well. So thanks everyone. Hope you have a nice evening.

Thank you, ladies and gentlemen. This does conclude today’s KemPharm third quarter 2022 earnings call and webcast. You may disconnect your line at this time and have a wonderful day.